EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study

Satoshi Yuki iD, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi iD, Hideaki Bando iD, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki iD und 9 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6486 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Satoshi Yuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biological Products, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several biomarkers have been established for metastatic colorectal cancer (mCRC). We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first‐line (1L) treatment in patients with RAS wild‐type mCRC and the dynamics of plasma angiogenesis factors at progression during 1L treatment.

Methods

In this multicenter prospective observational study, serial plasma samples were prospectively collected at pretreatment and progression stages; 17 plasma angiogenesis factors were analyzed using the multiplex assay with Luminex® technology. Interactions between the pretreatment measurements and treatment groups on progression‐free survival (PFS) and overall survival (OS) in patients with RAS wild‐type were assessed using the propensity‐score weighted Cox proportional hazards model.

Results

From February 2018 to September 2020, 202 patients were enrolled in the 1L cohort; 133 patients had RAS wild‐type (chemotherapy plus bevacizumab [BEV group, n = 33] and plus anti‐epidermal growth factor receptor monoclonal antibodies [aEGFR group, n = 100]). A trend of strong interaction on PFS was observed for interleukin‐8 (IL‐8) ( p = 0.0752) and soluble vascular cell adhesion molecule‐1 (sVCAM‐1) ( p = 0.0156). Regarding OS, IL‐8 ( p = 0.0283), soluble vascular endothelial growth factor‐receptor‐1 (sVEGFR‐1) ( p = 0.0777) and sVCAM‐1 ( p = 0.0011) tended to differentiate the treatment effect. In 112 patients, plasma samples were evaluable for dynamic analysis (57 and 55 from the BEV and aEGFR groups, respectively). In the BEV group, six factors significantly increased during progression, whereas two decreased. In the aEGFR group, three factors significantly increased, and six decreased.

Conclusion

Pretreatment plasma IL‐8 and sVCAM‐1 levels could be predictive biomarkers to distinguish BEV and anti‐EGFR mAbs when combined with chemotherapy in the 1L treatment of RAS wild‐type mCRC. Several plasma angiogenesis factors showed significant change at progression in 1L chemotherapy plus biologics for RAS wild‐type mCRC, which are potential biomarkers for selecting an optimal angiogenesis inhibitor in second‐line treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiological ProductsColonic NeoplasmsRectal NeoplasmsHumansInterleukin-8Vascular Endothelial Growth Factor AAntibodies, MonoclonalBevacizumabBiomarkersAntineoplastic Combined Chemotherapy ProtocolsFluorouracil

Stichwörter der Autor:innen

angiogenesisbiomarkerschemotherapycolorectal cancer

Substanzen

Interleukin-8Vascular Endothelial Growth Factor ABiological ProductsAntibodies, MonoclonalBevacizumabBiomarkersFluorouracil

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Taito Esaki, Hisato Kawakami, Hironaga Satake

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yuki, S., Yamazaki, K., Sunakawa, Y., Taniguchi, H., Bando, H., Shiozawa, M., Nishina, T., Yasui, H., Kagawa, Y., Takahashi, N., Denda, T., Esaki, T., Kawakami, H., Satake, H., Takashima, A., Matsuhashi, N., Kato, T., Asano, C., Abe, Y., …, & Yoshino, T. (2023). Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study. Cancer Medicine. https://doi.org/10.1002/cam4.6486

Vancouver

Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al. Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study. Cancer Medicine. 2023. doi:10.1002/cam4.6486

BibTeX
@article{Yuki2023,
  author = {Yuki, Satoshi and Yamazaki, Kentaro and Sunakawa, Yu and Taniguchi, Hiroya and Bando, Hideaki and Shiozawa, Manabu and Nishina, Tomohiro and Yasui, Hisateru and Kagawa, Yoshinori and Takahashi, Naoki and Denda, Tadamichi and Esaki, Taito and Kawakami, Hisato and Satake, Hironaga and Takashima, Atsuo and Matsuhashi, Nobuhisa and Kato, Takeshi and Asano, Chiharu and Abe, Yukiko and Nomura, Shogo and Yoshino, Takayuki},
  title = {Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6486}
}
Kostenlos starten →